Sorry - this product is no longer available
For active immunisation of breeding females from farms affected with European (genotype 1) Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) to reduce the duration of viraemia, the proportion of viraemic gilts/sows and viral loads in blood after exposure to PRRSV as shown under experimental conditions. Onset of immunity : 4 weeks Duration of immunity :17 weeks Vaccination of breeding females according to the recommended schedule described below reduces the negative reproductive disorders associated with PRRSV. Under experimental challenge conditions a reduction in transplacental virus transmission after challenge was additionally demonstrated. In piglets from vaccinated sows, a reduction in the negative impact of PRRS virus infection (mortality, clinical signs and weight gain) was also demonstrated during the first 20 days of life. Dosage and administration Single intramuscular injection of one dose (2 ml), irrespective of body weight. For reconstitution, transfer the entire content of the solvent vial to the vial containing the lyophilisate and reconstitute the lyophilisate as follows: 10 doses in 20 ml, 50 doses in 100 ml and 100 doses in 200 ml of the solvent. Ensure that the lyophilisate is completely reconstituted before use. Visual appearance after reconstitution: clear, colourless suspension. Avoid introduction of contamination during use. Use sterile equipment. Avoid multiple broaching, for example by using automatic injectors. Regime of vaccination: Gilts: for protection against PRRSV during pregnancy vaccination is recommended before integration into the sow herd between 2 and 5 weeks prior to breeding. Gilts can then be subjected to the same vaccination programme as the sow herd. Sows: mass vaccination is recommended in a whole herd programme, in which all the pregnant and non-pregnant sows in the herd are vaccinated every three to four months.
